emc易倍官网入口
We are laser-focused on developing innovative treatments within our three therapeutic areas: oncology, neuroscience and rare disease. We believe that concentrating on diseases and disorders within these areas, we can make a positive impact on the lives of patients and their families.
Our products are the result of decades of experience and years of research and development. We are proud of the portfolio of medicines we have brought to market, and we are determined in our efforts to find the next wave of treatments for patients.
emc易倍官网入口
- Bylvay? (odevixibat)
PI: Bylvay Product Information for Healthcare Professionals
CMI: Bylvay Consumer Medicine Information
- Cabometyx??(cabozantinib)
PI: Cabometyx Product Information for Healthcare Professionals
CMI: emc易倍官网入口Cabometyx Consumer Medicine Information
- Diphereline??(triptorelin embonate)
PI: Diphereline Product Information for Healthcare Professionals
CMI: emc易倍官网入口Diphereline Consumer Medicine Information
- Dysport??(clostridium botulinum type A toxin-haemagglutinin complex)
PI: Dysport Product Information for Healthcare Professionals
CMI: Dysport Consumer Medicine Information
- Iqirvo? (elafibranor)
PI: emc易倍官网入口Iqirvo Product Information for Healthcare Professionals
CMI: Iqirvo Consumer Medicine Information
- Sohonos? (palovarotene)
PI: Sohonos Product Information for Healthcare Professionals
CMI: Sohonos Consumer Medicine Information
- Somatuline??Autogel??(lanreotide acetate)
PI: Somatuline Product Information for Healthcare Professionals
Request medical information / report adverse event or product complaint
To request medical information on Ipsen’s products, report an adverse event or report a complaint, please email: emc易倍官网入口medinfo.australia@ipsen.com or call Ipsen AUSTRALIA (toll-free) on 1800 317 033 or Ipsen NEW ZEALAND (toll-free) on 0800 947 486.
Adverse event reactions can also be reported directly to Ipsen’s local safety team using the contact details provided in the contact us pages
